Amgen
Trade Amgen 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About AMGN
Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K.
AMGN Key Statistics
Stock Snapshot
Amgen(AMGN) stock is priced at $318.34, giving the company a market capitalization of 172.17B. It carries a P/E multiple of 24.56 and pays a dividend yield of 3.0%.
As of 2025-12-14, Amgen(AMGN) stock has fluctuated between $315.19 and $319.46. The current price stands at $318.34, placing the stock +1.0% above today's low and -0.3% off the high.
Amgen(AMGN) shares are trading with a volume of 2.25M, against a daily average of 2.85M.
In the last year, Amgen(AMGN) shares hit a 52-week high of $346.38 and a 52-week low of $253.30.
In the last year, Amgen(AMGN) shares hit a 52-week high of $346.38 and a 52-week low of $253.30.
AMGN News
Amgen Inc (AMGN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data a...
Amgen Inc (AMGN) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data a...
Amgen (AMGN) just picked up a meaningful FDA win, with Uplizna cleared as the first CD19 targeted B cell therapy for certain adults with generalized myasthenia...
Analyst ratings
45%
of 33 ratingsMore AMGN News
Amgen’s (AMGN) blinatumomab was granted FDA orphan designation as a treatment of acute lymphoblastic leukemia, according to a post to the agency’s website. Cla...
The U.S. Food and Drug Administration (FDA) on Thursday approved Amgen Inc.’s (NASDAQ:AMGN) Uplinza (inebilizumab-cdon) for generalized myasthenia gravis (gMG)....
Amgen AMGN announced that the FDA has approved its rare disease drug Uplizna (inebilizumab) for a new indication — generalized myasthenia gravis (gMG). The drug...
Amgen (AMGN) announced that the FDA has approved Uplinza, inebilizumab-cdon, for the treatment of generalized myasthenia gravis, gMG, in adults who are anti-ace...
(RTTNews) - Amgen (AMGN) announced that the U.S. Food and Drug Administration has approved UPLIZNA (inebilizumab-cdon) for the treatment of generalized myasthen...
HSBC raised the firm’s price target on Amgen (AMGN) to $425 from $381 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The f...